Preclinical studies of solid malignanciessuch as liposarcomas, breast, and colon cancers also provide support for the greaterefficacy of combined regimens of PPARγ and RXR ligands compared to monotherapy [26, 80, 115]. This evidence concerns the gene PPARG and malignant colon neoplasm.